Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents - Drug Trials For Money - Paid Clinical Trials

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Conditions:   Fallopian Tube Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Platinum-Refractory Fallopian Tube Carcinoma;   Platinum-Refractory Ovarian Carcinoma;   Platinum-Refractory Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Clear Cell Adenocarcinoma;   Recurrent Fallopian Tube Endometrioid Adenocarcinoma;   Recurrent Fallopian Tube High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Mucinous Adenocarcinoma;   Recurrent Fallopian Tube Transitional Cell Carcinoma;   Recurrent Fallopian Tube Undifferentiated Carcinoma;   Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma;   Recurrent Ovarian Clear Cell Adenocarcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Ovarian High Grade Serous Adenocarcinoma;   Recurrent Ovarian Low Grade Serous Adenocarcinoma;   Recurrent Ovarian Mucinous Adenocarcinoma;   Recurrent Ovarian Seromucinous Carcinoma;   Recurrent Ovarian Transitional Cell Carcinoma;   Recurrent Ovarian Undifferentiated Carcinoma;   Recurrent Platinum-Resistant Fallopian Tube Carcinoma;   Recurrent Platinum-Resistant Ovarian Carcinoma;   Recurrent Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Primary Peritoneal Clear Cell Adenocarcinoma;   Recurrent Primary Peritoneal Endometrioid Adenocarcinoma;   Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma;   Recurrent Primary Peritoneal Transitional Cell Carcinoma;   Recurrent Primary Peritoneal Undifferentiated Carcinoma;   Refractory Fallopian Tube Clear Cell Adenocarcinoma;   Refractory Fallopian Tube Endometrioid Adenocarcinoma;   Refractory Fallopian Tube High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Mucinous Adenocarcinoma;   Refractory Fallopian Tube Transitional Cell Carcinoma;   Refractory Fallopian Tube Undifferentiated Carcinoma;   Refractory Low Grade Fallopian Tube Serous Adenocarcinoma;   Refractory Ovarian Clear Cell Adenocarcinoma;   Refractory Ovarian Endometrioid Adenocarcinoma;   Refractory Ovarian High Grade Serous Adenocarcinoma;   Refractory Ovarian Low Grade Serous Adenocarcinoma;   Refractory Ovarian Mucinous Adenocarcinoma;   Refractory Ovarian Seromucinous Carcinoma;   Refractory Ovarian Transitional Cell Carcinoma;   Refractory Ovarian Undifferentiated Carcinoma;   Refractory Primary Peritoneal Clear Cell Adenocarcinoma;   Refractory Primary Peritoneal Endometrioid Adenocarcinoma;   Refractory Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma;   Refractory Primary Peritoneal Transitional Cell Carcinoma;   Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions:   Drug: Cediranib Maleate;   Biological: Durvalumab;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Topotecan Hydrochloride
Sponsors:   National Cancer Institute (NCI);   NRG Oncology
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022 / by / in
Comments